TY - JOUR
T1 - Allogeneic transplantation for advanced acute myeloid leukemia
T2 - The value of complete remission
AU - Weisdorf, Daniel J.
AU - Millard, Heather R.
AU - Horowitz, Mary M.
AU - Hyare, Parvinder S.
AU - Champlin, Richard
AU - Ho, Vincent
AU - Mielcarek, Marco
AU - Rezvani, Andrew
AU - Stockerl-Goldstein, Keith
AU - Khoury, Hanna J.
AU - De Lima, Marcos
AU - Saber, Wael
AU - Sandmaier, Brenda
AU - Zhang, Mei Jie
AU - Eapen, Mary
N1 - Publisher Copyright:
© 2017 American Cancer Society
PY - 2017/6/1
Y1 - 2017/6/1
N2 - BACKGROUND: Patients with acute myeloid leukemia (AML) without complete remission (CR) or in first relapse (Rel1) can have extended leukemia control and survival after allogeneic hematopoietic cell transplantation (HCT). For patients in Rel1 or primary induction failure (PIF), transplantation versus treatment to achieve a second CR (CR2) and subsequent HCT might yield similar outcomes, but available comparative data are scarce. METHODS: Survival was analyzed in 4682 HCT recipients according to disease status: PIF (N = 1440), Rel1 (failing ≥1 reinduction; N = 1256), and CR2 (N = 1986). RESULTS: Patient, disease, and transplantation characteristics were similar, except that patients in CR2 more often had performance scores of 90% to 100%, de novo AML, and longer CR1 duration. Adverse cytogenetics were more common in patients who experienced PIF. The 5-year survival rate adjusted for performance score, cytogenetic risk, and donor type for CR2 was 39% (95% confidence interval [CI], 37%-41%) compared with 18% (95% CI, 16%-20%) for HCT in Rel1 and 21% (95% CI, 19%-23%) in PIF (P <.0001). CONCLUSIONS: Although survival is superior for patients who undergo HCT in CR2, transplantation for selected patients in Rel1 or PIF may still be valuable. These data can guide decision making about additional salvage therapy versus prompt HCT for patients not in CR, but they also highlight that AML is intrinsically more treatable in patients who have favorable-risk cytogenetics, those with longer CR1 duration, and younger patients with better performance status. Cancer 2017;123:2025–2034.
AB - BACKGROUND: Patients with acute myeloid leukemia (AML) without complete remission (CR) or in first relapse (Rel1) can have extended leukemia control and survival after allogeneic hematopoietic cell transplantation (HCT). For patients in Rel1 or primary induction failure (PIF), transplantation versus treatment to achieve a second CR (CR2) and subsequent HCT might yield similar outcomes, but available comparative data are scarce. METHODS: Survival was analyzed in 4682 HCT recipients according to disease status: PIF (N = 1440), Rel1 (failing ≥1 reinduction; N = 1256), and CR2 (N = 1986). RESULTS: Patient, disease, and transplantation characteristics were similar, except that patients in CR2 more often had performance scores of 90% to 100%, de novo AML, and longer CR1 duration. Adverse cytogenetics were more common in patients who experienced PIF. The 5-year survival rate adjusted for performance score, cytogenetic risk, and donor type for CR2 was 39% (95% confidence interval [CI], 37%-41%) compared with 18% (95% CI, 16%-20%) for HCT in Rel1 and 21% (95% CI, 19%-23%) in PIF (P <.0001). CONCLUSIONS: Although survival is superior for patients who undergo HCT in CR2, transplantation for selected patients in Rel1 or PIF may still be valuable. These data can guide decision making about additional salvage therapy versus prompt HCT for patients not in CR, but they also highlight that AML is intrinsically more treatable in patients who have favorable-risk cytogenetics, those with longer CR1 duration, and younger patients with better performance status. Cancer 2017;123:2025–2034.
KW - acute myeloid leukemia
KW - allogeneic transplantation
KW - complete remission
KW - primary induction failure
KW - relapse
UR - http://www.scopus.com/inward/record.url?scp=85019595123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019595123&partnerID=8YFLogxK
U2 - 10.1002/cncr.30536
DO - 10.1002/cncr.30536
M3 - Article
C2 - 28117884
AN - SCOPUS:85019595123
SN - 0008-543X
VL - 123
SP - 2025
EP - 2034
JO - Cancer
JF - Cancer
IS - 11
ER -